Bioxcel Therapeutics Logo
Previous slide
Next slide

Our AI-based approach is designed to:

  • Enhance R&D efficiencies
  • Shorten development timelines
  • Increase probability of success

Latest News

VIEW ALL NEWS
Mar 11, 2025
BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaVIEW RELEASE
Mar 07, 2025
BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaVIEW RELEASE
Mar 04, 2025
BioXcel Therapeutics Announces Closing of $14 Million Registered Direct OfferingVIEW RELEASE
VIEW ALL NEWS

Stock Information

BioXcel Therapeutics, Inc.

Mar 21, 2025 04:00 PM

MARKET/SYMBOL

Nasdaq:

BTAI

PRICE

2.33

CHANGE

-0.03 (-1.27%)
EVENTS
SIGN UP FOR EMAIL ALERTS
Bioxcel Therapeutics Logo
Linkedin-in Twitter

IGALMI is a registered trademark of BioXcel Therapeutics, Inc. 
All other trademarks are the properties of their respective owners.
Copyright © 2025 BioXcel Therapeutics Inc. All Rights Reserved. US-IGA-2300177

IGALMI is a registered trademark of BioXcel Therapeutics, Inc.
All other trademarks are the properties of their respective owners.
Copyright © 2025 BioXcel Therapeutics Inc. All Rights Reserved. US-IGA-2300177

Scroll to Top

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries. This web site is intended to help healthcare professionals practicing in the US find scientifically balanced, evidence-based information about Bioxcel Therapeutics drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.